Presentation is loading. Please wait.

Presentation is loading. Please wait.

Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.

Published byJemimah Marsh Modified over 5 years ago

Similar presentations

Presentation on theme: "Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response."— Presentation transcript:

1 Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.
Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response. At the end of the efficacy study as described in Fig. 1D, splenocytes were isolated and fresh frozen. Viable cells after thaw were rested for 12 hours and challenged with CD8-restricted MC38 immunodominant peptide KSPWFTTL ex vivo. IFNγ production was assessed by ELISpot. The number of spots, an indication of the number of IFNγ-producing cells, was reported. Each symbol represents an individual animal within the same treatment group. *, P < 0.05 and ****, P < , when comparing groups as indicated by the horizontal lines. Shihao Chen et al. Cancer Immunol Res 2015;3: ©2015 by American Association for Cancer Research

Download ppt "Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response."

Similar presentations

Fig. 1. TLR4 expression is much greater on macrophages than on DCs

Fig. 1. TLR4 expression is much greater on macrophages than on DCs
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Uptake of T-MPs for DC maturation and antigen presentation.

Uptake of T-MPs for DC maturation and antigen presentation.
Volume 8, Issue 2, Pages (February 1998)

Volume 8, Issue 2, Pages (February 1998)
The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.
Cetuximab treatment increases IFNγ receptor 1 expression.

Cetuximab treatment increases IFNγ receptor 1 expression.
ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Anti-IL2 restores the Th17 response to ETBF in the absence of FOXP3+ Tregs. Anti-IL2 restores the Th17 response to ETBF in the absence of FOXP3+ Tregs.

Anti-IL2 restores the Th17 response to ETBF in the absence of FOXP3+ Tregs. Anti-IL2 restores the Th17 response to ETBF in the absence of FOXP3+ Tregs.
The absence of ADCC by nivolumab in vitro.

The absence of ADCC by nivolumab in vitro.
Administration of pIL2 and pgDE7 induces higher activation of E7-specific Tem CD8+ T cells. Administration of pIL2 and pgDE7 induces higher activation.

Administration of pIL2 and pgDE7 induces higher activation of E7-specific Tem CD8+ T cells. Administration of pIL2 and pgDE7 induces higher activation.
Viperin−/−mice have an increased IFNγ Th1 response.

Viperin−/−mice have an increased IFNγ Th1 response.
Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.
Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Anti-SEMA4D and anti–CTLA-4 treatment is synergistic and increases the frequency of tumor-specific TILs and secretion of proinflammatory cytokines, while.

Anti-SEMA4D and anti–CTLA-4 treatment is synergistic and increases the frequency of tumor-specific TILs and secretion of proinflammatory cytokines, while.
Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.
CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.
ABT-199 efficiently kills primary AML myeloblasts as a single agent.

ABT-199 efficiently kills primary AML myeloblasts as a single agent.
Exosome-mediated inhibition of T cells is reversible.

Exosome-mediated inhibition of T cells is reversible.

Similar presentations

Ads by Google